Last reviewed · How we verify

K. Lieb — Portfolio Competitive Intelligence Brief

K. Lieb pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Escitalopram, venlafaxine, lithium Escitalopram, venlafaxine, lithium marketed Antidepressant combination (SSRI + SNRI + mood stabilizer) Serotonin transporter (SERT), norepinephrine transporter (NET), and lithium-responsive intracellular signaling pathways Psychiatry / Mental Health
Escitalopram, venlafaxine Escitalopram, venlafaxine marketed SSRI/SNRI combination Serotonin transporter (SERT); norepinephrine transporter (NET) Psychiatry/Mental Health

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ministry of Health & Welfare, Korea · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for K. Lieb:

Cite this brief

Drug Landscape (2026). K. Lieb — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/k-lieb. Accessed 2026-05-14.

Related